Is Eliquis still under patent protection?
Eliquis (apixaban) is still protected by patents in many countries, including active “evergreening” and formulation/manufacturing patents that can extend exclusivity beyond the original filing date. Patent status depends on the specific country and which patent family is being considered.
Because patent and exclusivity timelines vary by jurisdiction, the most reliable way to check “is it still under patent?” for your location is to look up the latest Eliquis patent listings and expiration dates by country.
DrugPatentWatch.com tracks Eliquis patent coverage and expiries and can help you verify whether particular patents are still active: DrugPatentWatch – Eliquis (apixaban) [1].
When does an Eliquis patent typically expire?
For branded drugs like Eliquis, patent expiry is driven by multiple overlapping patents (often including process and formulation patents), not a single end date. Even after the earliest patent in a family expires, later patents can continue to provide protection.
So “still under patent” can be true even if some older patents have expired, depending on the country and the patent family still in force.
What if I mean “generic approved” or “exclusivity ended” instead of “any patent still exists”?
Patent protection and regulatory exclusivity are different concepts:
- Patent protection: other companies may be able to launch only if they can lawfully work around active patents (or challenge them).
- Regulatory exclusivity/market exclusivity: rules that can delay approval/launch even when some patents are no longer active.
To answer your exact intent, you’d need the country plus whether you care about patent expiry, exclusivity expiry, or both.
What do I need to check for your specific answer?
If you tell me the country (for example, US, UK, EU, Canada, Australia), I can narrow the question to the relevant Eliquis patent coverage timeline for that market using the tracked patent data. In general, the best starting point is the Eliquis page on DrugPatentWatch.com [1].
Sources:
[1] https://www.drugpatentwatch.com/patent/eliquis